09:51 AM EST - InMed Pharmaceuticals Inc. : Announced that all subjects participating in its 755-101-HV Phase 1 clinical trial have completed treatment and clinical evaluation. Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period. With treatment completed, InMed continues to anticipate reporting final study results in the second half of calendar 2020. InMed Pharmaceuticals Inc.
shares T.IN are trading down $0.015 at $0.21.
